CYTK Q2 2023 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$867,000-99.0% YoY

Gross Profit

-$82M-9495.6% margin

Operating Income

-$122M-14077.2% margin

Net Income

-$129M-14837.0% margin

EPS (Diluted)

$-1.34

QoQ Revenue Growth

-81.2%

Cash Flow

Operating Cash Flow

-$122M

Free Cash Flow

-$123M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$780M

Total Liabilities

$1.1B

Stockholders' Equity

-$333M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$867,000	$89M	-99.0%
Gross Profit	-$82M	$32M	-358.5%
Operating Income	-$122M	-$11M	-1022.4%
Net Income	-$129M	-$20M	-549.0%

Revenue Segments

Research And Development

$867,000100%